Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for Bright Minds Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan ...

Fintel reports that on January 23, 2025, Piper Sandler initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a ...

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including ...

Piper Sandler initiated coverage on Bright Minds Biosciences Inc. (NASDAQ: DRUG), assigning the stock an Overweight rating and setting a price target of $93.00. With a current market capitalization of ...

Bright Minds Biosciences (DRUG) has received a new Buy rating, initiated by Piper Sandler analyst, Yasmeen Rahimi.Invest with Confidence: ...

Piper Sandler initiated coverage of Bright Minds Biosciences (DRUG) with an Overweight rating and $93 price target The firm believes the ...

Advancements in precision medicine drive the 5-HT2 agonist market by enabling selective targeting of specific receptor subtypes (e.g., 5-HT2A or 5-HT2C), reducing side effects and improving safety.

We've identified the following companies as similar to Bright Minds Biosciences Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company ...